Telix Pharmaceuticals Limited
TLPPF
$16.05
-$0.1419-0.88%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 3.75% | 6.17% | 297.71% | 303.65% | 158.32% |
| Total Depreciation and Amortization | 21.70% | 24.55% | 17.66% | 5.50% | 32.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 107.25% | 112.10% | 31.73% | -235.51% | -24.93% |
| Change in Net Operating Assets | -91.80% | -96.28% | -- | -- | -3,197.52% |
| Cash from Operations | -62.85% | -61.98% | 206.68% | 115.07% | 380.68% |
| Capital Expenditure | -261.15% | -269.60% | -65.90% | -39.97% | -41.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -6,157.86% | -6,302.73% | -18,689.42% | -- | 87.47% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -263.89% | -272.40% | -- | -- | -62,726.83% |
| Cash from Investing | -295.18% | -304.41% | -2,814.44% | -424.13% | -295.58% |
| Total Debt Issued | 19,864.49% | 19,864.49% | 46.78% | -18.01% | 8.56% |
| Total Debt Repaid | -28.99% | -28.99% | -199.75% | -- | -78.61% |
| Issuance of Common Stock | -90.20% | -90.20% | -78.28% | -78.52% | 129.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 11,508.06% | 11,779.46% | 27.52% | -174.11% | 43.44% |
| Foreign Exchange rate Adjustments | 2,106.88% | 2,153.78% | -107.19% | 82.19% | -202.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7,064.59% | 7,227.32% | -136.81% | -110.13% | -34.02% |
